Is Sunitinib on the market?

Sunitinib (Sunitinib)'s trade name is Sutent. It is an anti-cancer drug. It is a small molecule, multi-target receptor tyrosine Kinase (RTK) inhibitors were approved by the U.S. Food and Drug Administration (FDA) in January 2006 for the treatment of renal cell carcinoma (RCC) and imatinib-resistant gastrointestinal stromal tumors (GIST). Sunitinib is the first cancer drug approved for two different indications simultaneously.

For these purposes, sunitinib is usually provided as an oral preparation. Sunitinib inhibits cell signaling by targeting multiple RTKs. Includes all platelet-derived growth factor receptors (PDGF-R) and vascular endothelial growth factor receptors (VEGF-R). Sunitinib also inhibits KIT (CD117), the RTK that drives most GISTs. In addition, sunitinib inhibits other RTKs, including RET, CSF-1R, and flt3.

The original sunitinib drug has been launched in China and has entered the scope of Class B medical insurance. SpecificationsThe price of 12.5mg*28 tablets is around RMB 3,500. The original sunitinib drug has also been launched overseas. The price of 12.5mg*7 tablets is around RMB 1,500 (the price may fluctuate due to the exchange rate). There are also generic drugs produced in other countries. The price of 12.5mg*28 tablets produced by an Indian pharmaceutical factory is around RMB 750 (the price may fluctuate due to the exchange rate). The generic drugs produced abroad are basically the same as the original drugs at home and abroad. There may be differences in the prices of different specifications of drugs.